• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溃疡性结肠炎未满足的医疗需求:专家组共识

Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.

作者信息

Danese Silvio, Allez Matthieu, van Bodegraven Ad A, Dotan Iris, Gisbert Javier P, Hart Ailsa, Lakatos Peter L, Magro Fernando, Peyrin-Biroulet Laurent, Schreiber Stefan, Tarabar Dino, Vavricka Stephan, Halfvarson Jonas, Vermeire Séverine

机构信息

Humanitas Research Hospital, Milan, Italy.

Department of Gastroenterology and Hepatology, Hôpital Saint-Louis, Paris, France.

出版信息

Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.

DOI:10.1159/000496739
PMID:30726845
Abstract

BACKGROUND

The authors aimed to conduct an extensive literature review and consensus meeting to identify unmet needs in ulcerative colitis (UC) and ways to overcome them. UC is a relapsing and remitting inflammatory bowel disease with varied, and changing, incidence rates worldwide. UC has an unpredictable disease course and is associated with a high health economic burden. During 2016 and 2017, a panel of experts was convened to identify, discuss and address areas of unmet need in UC.

METHODS

PubMed and Cochrane Library databases were searched for relevant articles describing studies performed in patients with UC. These findings were used to generate a set of statements relating to unmet needs in UC. Consensus on these statements was then sought from a panel of 9 expert gastroenterologists using a modified Delphi review process that consisted of anonymous surveys followed by live meetings.

RESULTS

In 2 literature reviews, over 5,000 unique records were identified and a total of 138 articles were fully reviewed. These were used to consider 26 areas of unmet need, which were explored in 2 face-to-face meetings, in which the statements were debated and amended, resulting in consensus on 30 final statements. The unmet needs identified were categorised into 7 areas: impact of UC on patients' daily life; importance of early diagnosis and treatment; drawbacks of existing treatments; urgent need for new treatments; and disease-, practice- or patient-focused unmet needs.

CONCLUSIONS

These expert group meetings found a number of areas of unmet needs in UC, which is an important first step in tackling them in the future. Future research and development should be focused in these areas for the management of patients with UC.

摘要

背景

作者旨在进行广泛的文献综述和共识会议,以确定溃疡性结肠炎(UC)中未满足的需求以及克服这些需求的方法。UC是一种复发缓解型炎症性肠病,全球发病率各不相同且不断变化。UC的疾病进程不可预测,且与高昂的健康经济负担相关。在2016年至2017年期间,召集了一个专家小组来识别、讨论和解决UC中未满足需求的领域。

方法

在PubMed和Cochrane图书馆数据库中搜索描述在UC患者中进行的研究的相关文章。这些研究结果被用于生成一组与UC中未满足需求相关的陈述。然后,使用改良的德尔菲评审过程,从9名胃肠病学专家组成的小组中寻求对这些陈述的共识,该过程包括匿名调查和现场会议。

结果

在两项文献综述中,识别出了超过5000条独特记录,共对138篇文章进行了全面评审。这些被用于考虑26个未满足需求的领域,在两次面对面会议中对这些领域进行了探讨,在会议中对陈述进行了辩论和修改,最终就30条最终陈述达成了共识。确定的未满足需求被分为7个领域:UC对患者日常生活的影响;早期诊断和治疗的重要性;现有治疗的缺点;对新治疗的迫切需求;以及以疾病、实践或患者为重点的未满足需求。

结论

这些专家组会议发现了UC中一些未满足需求的领域,这是未来解决这些问题的重要第一步。未来的研发应聚焦于这些领域,以管理UC患者。

相似文献

1
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.溃疡性结肠炎未满足的医疗需求:专家组共识
Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.
2
SURGICAL MANAGEMENT OF ADULT CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS: A CONSENSUS FROM THE BRAZILIAN ORGANIZATION OF CROHN'S DISEASE AND COLITIS (GEDIIB).成人克罗恩病和溃疡性结肠炎患者的手术治疗:来自巴西克罗恩病和结肠炎组织(GEDIIB)的共识
Arq Gastroenterol. 2023 Mar 24;59(suppl 1):1-19. doi: 10.1590/S0004-2803.2022005S1-01. eCollection 2023.
3
Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists.溃疡性结肠炎的争议:一项比较专家与社区胃肠病学家决策的调查
Clin Gastroenterol Hepatol. 2009 Feb;7(2):168-74, 174.e1. doi: 10.1016/j.cgh.2008.08.029. Epub 2008 Sep 4.
4
Predicting Outcomes in Pediatric Ulcerative Colitis for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program.为了优化管理,预测小儿溃疡性结肠炎的结局:来自小儿炎症性肠病-前瞻性计划的系统评价和共识声明。
Gastroenterology. 2021 Jan;160(1):378-402.e22. doi: 10.1053/j.gastro.2020.07.066. Epub 2020 Sep 23.
5
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia.亚洲溃疡性结肠炎的流行病学、疾病负担和治疗需求未满足情况。
Expert Rev Gastroenterol Hepatol. 2021 Mar;15(3):275-289. doi: 10.1080/17474124.2021.1840976. Epub 2021 Jan 19.
6
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus.溃疡性结肠炎管理中未满足的医疗需求:意大利德尔菲共识的结果
Gastroenterol Res Pract. 2019 Sep 2;2019:3108025. doi: 10.1155/2019/3108025. eCollection 2019.
7
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations.定义综合疾病控制作为临床实践中溃疡性结肠炎的治疗目标:国际德尔菲共识推荐
J Crohns Colitis. 2024 Jan 27;18(1):91-105. doi: 10.1093/ecco-jcc/jjad130.
8
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.轻度至中度溃疡性结肠炎的实用管理:国际专家共识。
Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650. Epub 2024 Sep 3.
9
Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain.西班牙的一项真实生活调查:胃肠病学家对溃疡性结肠炎欧洲克罗恩病和结肠炎组织共识的依从性。
J Crohns Colitis. 2010 Nov;4(5):567-74. doi: 10.1016/j.crohns.2010.06.001. Epub 2010 Jul 6.
10
Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.非住院溃疡性结肠炎的医学管理临床实践指南:多伦多共识。
Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4.

引用本文的文献

1
Gastroprotective Effects of S-Adenosyl-L-Methionine Through Its Antioxidant and Anti-inflammatory Properties on Dextran Sulfate Sodium-Induced Chronic Colitis in Swiss Albino Mice.S-腺苷-L-甲硫氨酸通过其抗氧化和抗炎特性对葡聚糖硫酸钠诱导的瑞士白化小鼠慢性结肠炎的胃保护作用
Cureus. 2025 Jun 16;17(6):e86175. doi: 10.7759/cureus.86175. eCollection 2025 Jun.
2
MH002, a Novel Butyrate-Producing Consortium of Six Commensal Bacterial Strains Has Immune-Modulatory and Mucosal-Healing Properties.MH002,一种由六种共生细菌菌株组成的新型产丁酸盐菌群,具有免疫调节和黏膜修复特性。
Int J Mol Sci. 2025 Jun 26;26(13):6167. doi: 10.3390/ijms26136167.
3
Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.
乌帕替尼治疗中度至重度活动性溃疡性结肠炎患者长期治疗目标的达成:一项3期试验数据的事后分析
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjaf095.
4
Unmet Healthcare Needs Among People with Inflammatory Bowel Disease: A Canadian Cross-Sectional Population-Representative Study.炎症性肠病患者未满足的医疗需求:一项加拿大横断面人群代表性研究。
Dig Dis Sci. 2025 Apr 2. doi: 10.1007/s10620-025-09015-w.
5
Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies.使用瑞莎珠单抗治疗溃疡性结肠炎患者的症状缓解及生活质量的显著改善:INSPIRE和COMMAND随机研究的事后分析
Am J Gastroenterol. 2025 Mar 17;120(8):1820-8. doi: 10.14309/ajg.0000000000003420.
6
Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta‑analysis of randomized controlled trials.白细胞介素-23抑制剂作为中重度溃疡性结肠炎的诱导和维持治疗:一项随机对照试验的系统评价和荟萃分析
Inflamm Res. 2025 Mar 8;74(1):50. doi: 10.1007/s00011-025-02017-4.
7
Efficacy and safety of two-step acupuncture therapy for symptom relief in adults with mild to moderate ulcerative colitis: rationale and design of the TSA-UC randomised controlled trial.两步针刺疗法缓解轻至中度溃疡性结肠炎成年患者症状的疗效和安全性:TSA-UC随机对照试验的原理与设计
BMJ Open. 2025 Feb 27;15(2):e094301. doi: 10.1136/bmjopen-2024-094301.
8
Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial.中性粒细胞调节剂ADS051治疗溃疡性结肠炎的安全性、药代动力学及临床疗效:一项随机1b期试验的结果
Am J Gastroenterol. 2024 Dec 31;120(7):1624-1635. doi: 10.14309/ajg.0000000000003269.
9
Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study.在 filgotinib 治疗期间溃疡性结肠炎症状反应的不同轨迹:SELECTION 研究的事后分析。
United European Gastroenterol J. 2024 Nov;12(9):1243-1255. doi: 10.1002/ueg2.12686. Epub 2024 Oct 25.
10
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.溃疡性结肠炎连续治疗152周后mirikizumab的三年疗效和安全性:LUCENT-3开放标签扩展研究结果
Inflamm Bowel Dis. 2024 Oct 25. doi: 10.1093/ibd/izae253.